Literature DB >> 3351676

Minor anomalies in offspring of epileptic mothers.

E Gaily1, M L Granström, V Hiilesmaa, A Bardy.   

Abstract

In a prospective study, 121 children of mothers with epilepsy (study group) and 105 control children were examined in a blinded fashion at age 5 1/2 years for 80 minor physical anomalies, including nine typical features previously reported characteristic of fetal hydantoin syndrome. Of the study group, 106 children had been exposed to antiepileptic drugs (82 to phenytoin) during pregnancy; 44 (36%) mothers had had generalized convulsions during pregnancy. One hundred fourteen mothers and 87 fathers of study group children and 101 mothers and 58 fathers of control children were also examined. A significant excess of minor anomalies considered characteristic of hydantoin syndrome was observed in children of epileptic mothers and in epileptic mothers, compared with the control group. There was no excess of other minor anomalies studied. Several minor anomalies previously regarded as typical of fetal hydantoin syndrome were shown to be genetically linked to epilepsy. Only hypertelorism and digital hypoplasia were associated with phenytoin exposure. The current concept of the syndrome seems to be incorrect; most of the "typical" characteristics are not caused by phenytoin. None of the phenytoin-exposed children had all of the main characteristics of hydantoin syndrome (typical acrofacial features, intellectual deficiency, growth retardation, and microcephaly). The risk of developmental disturbance associated with intrauterine phenytoin exposure seems to be much lower than the 7% to 11% risk of fetal hydantoin syndrome reported earlier.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351676     DOI: 10.1016/s0022-3476(88)80162-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Developmental neuropathology of environmental agents.

Authors:  Lucio G Costa; Michael Aschner; Annabella Vitalone; Tore Syversen; Offie Porat Soldin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

Review 2.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 3.  Treatment of epilepsy in pregnancy.

Authors:  I Nulman; D Laslo; G Koren
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Additional educational needs in children born to mothers with epilepsy.

Authors:  N Adab; A Jacoby; D Smith; D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

Review 5.  Risk-benefit assessment of anticonvulsants in women of child-bearing potential.

Authors:  P G Cleland
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

6.  Fetal phenytoin exposure, hypoplastic nails, and jitteriness.

Authors:  S W D'Souza; I G Robertson; D Donnai; G Mawer
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

7.  Dysmorphic features in offspring of alcoholic mothers.

Authors:  I Autti-Rämö; E Gaily; M L Granström
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

Review 8.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

10.  Increased prevalence of minor physical anomalies in patients with epilepsy.

Authors:  Dalma Tényi; Tamás Tényi; Györgyi Csábi; Sára Jeges; Beáta Bóné; Katalin Lőrincz; Norbert Kovács; József Janszky
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.